| Document |
Document Title |
|
JP4463420B2 |
Disclosed are novel compounds useful for prevention or control of diseases derived from fungi, a process for producing the same, and novel antifungal agents using the novel compounds. The compounds useful for prevention and treatment of ...
|
|
JP2010090086A |
To provide a new SGLT (Sodium-dependent GLucose Transporter) inhibitor useful for treating hyperglycemia, and to provide a pharmaceutical composition containing the same and useful for treating diabetes and complications related thereto....
|
|
JP4450922B2 |
|
|
JP4433137B2 |
PURPOSE: A method for preserving cyclic formal is provided, thereby preserving monomer having improved thermostability for production of polyoxymethylene copolymer without reduction of quality. CONSTITUTION: The method for preserving cyc...
|
|
JP4425545B2 |
The invention relates to chiral compounds of formula I wherein X1, X2, X1, X2, x1, x2, y1, y2, B, C, U1, U2, V1, V2, W1 and W2 have the meaning given in claim 1 , to liquid crystal mixtures comprising at least one chiral compound of form...
|
|
JP4418554B2 |
The compounds according to the general formula in which formula the dotted lines indicate a single or a double bond, n and m are 0 or 1, R<1> is hydrogen or an acyl group -C(O)R<3>, R<3> being a linear or branched alkyl or alkylene group...
|
|
JP4376981B2 |
Disclosed are odorant compounds having 14- to 17-membered 4-methyl substituted 1,7-dioxacycloalkan-8-ones and 14- to 16-membered 1,7-dioxacycloalkan-8-ones with 4,4-dimethyl substitution. Also disclosed are methods of odorizing a substan...
|
|
JP2009539762A |
This invention is directed to a compound of formula (I), as defined herein, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing a compound of formula (I) a process of en preparation of a compound of for...
|
|
JP2009537635A |
The present invention is directed to co-therapy for the treatment of epilepsy and related disorders comprising administering to a subject in need thereof, co-therapy with a therapeutically effective amount of a benzo-fused heterocycle su...
|
|
JP2009536946A |
A compound having a structure according to formula I wherein R1, R2, R3, R4, and R5 are as defined herein, are useful as kinase inhibitors.
|
|
JP4329306B2 |
|
|
JP2009192543A |
To provide labeling reagents, labeled targets, and processes for preparing labeling reagents.The labeling reagents can take the form of cyanine dyes, xanthene dyes, porphyrin dyes, coumarin dyes or composite dyes. These labeling reagents...
|
|
JP4322051B2 |
|
|
JP2009167199A |
To provide a 2 adrenergic receptor agonist with improved characteristics.The adrenergic receptor agonist compound is represented by the formula. A pharmaceutical composition comprising the compound, a method of using the compound to trea...
|
|
JP4303113B2 |
The invention provides novel beta2 adrenergic receptor agonist compounds of formula (I): wherein R1-R13 and w have any of the values described in the specification. The invention also provides pharmaceutical compositions comprising such ...
|
|
JP4290765B2 |
Novel derivatives of benzodioxa alkylene ethers are provided which are useful as melatonergic agents.
|
|
JP4278511B2 |
Disclosed are compounds of the formula (I): useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and ot...
|
|
JP2009520037A |
The present invention is a method for treating, preventing, reversing, arresting or inhibiting the occurrence, development and maturation of seizures or seizure-related disorders. More specifically, the present invention is directed to m...
|
|
JP4266638B2 |
Novel PDF inhibitors and novel methods for their use are provided.
|
|
JP4262477B2 |
The invention relates to a process for the preparation of cyclic carboxylic acid orthoester fluorides in which a) at least one bis(alkylthio)carbenium salt is reacted with at least one organic compound containing at least two hydroxyl gr...
|
|
JP2009514799A |
The invention relates to chiral compounds, methods of their preparation, and to their use in optical, electrooptical, electronic, semiconducting or luminescent components or devices, and in decorative, security, cosmetic or diagnostic ap...
|
|
JP2009511589A |
The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal depositi...
|
|
JP4224566B2 |
A medicament having inhibitory activity against NF- º B activation, which comprises a compound represented by the following general formula (I) or a pharmacologically acceptable salt as an active ingredient: wherein X represents a conne...
|
|
JP4213205B2 |
The invention relates to compounds of formula: wherein R1 is selected from the group consisting of fatty acid acyl groups of 12 to 30 carbon atoms and fatty alcohol groups of 12 to 30 carbon atoms, and wherein R2 is selected from the gro...
|
|
JP4199830B2 |
Stable, enzymatically triggered chemiluminescent 1,2-dioxetanes with improved water solubility and storage stability are provided. Dioxetanes further substituted with two or more water-solubilizing groups disposed on the dioxetane struct...
|
|
JP2008545682A |
The invention concerns novel 1,2-dioxetane derivatives of general formula (I) as defined in the description, capable of emitting a detectable luminescent signal, their use in a method for detecting and/or quantizing a physical, chemical ...
|
|
JP2008542192A |
The present invention provides novel honokiol derivatives, as well as pharmaceutical compositions containing the honokiol derivatives. These compounds and pharmaceutical compositions can be used in the prevention and/or treatment of canc...
|
|
JP2008260760A |
To provide a pharmaceutical composition excellent in prevention and/or therapy of diseases such as septicemia, a compound able to be used for the same and a method for producing the same.The pharmaceutical composition contains a compound...
|
|
JP4171097B2 |
Benzoxepine and benzocycloheptane derivatives of formula (I), their stereoisomers and salts are new. X1 = O, S, SO, SO2, CR1R2, NR6, CO or CR1R7; R1, R2 = H, CF3, C2F5, C3F7, 1-6C alkyl or phenyl (optionally substituted by 1 or 2 of halo...
|
|
JP4156367B2 |
The invention relates to a process for the preparation of compounds containing at least one -CF2-O- bridge in the molecule, in which a) an acid is added onto at least one ketene dithioketal, b) the resultant bis(alkylthio)carbenium salt ...
|
|
JP4148702B2 |
The present invention provides a novel phosphine compound, specifically to provide a novel phosphine compound useful as a ligand for the above catalysts, in particular, a novel catalyst having an excellent performance (chemical selectivi...
|
|
JP4142165B2 |
7-Propyl-2H,4H-1,5-benzodioxepin-3-one (I) is used in perfumery. Independent claims are included for its use in perfumery, particularly in perfumes, toilet waters, cosmetics, shampoos, soaps, bath and shower gels, deodorants, antiperspir...
|
|
JP2008532983A |
Compounds of the general formula (I) in which the meanings of the substituents R1 and R2 are as stated in claim 1 , have renin-inhibiting properties and can be used as medicines.
|
|
JP4137436B2 |
The present invention provides an optically active compound represented by the following general formula (1), a photoreactive chiral agent, a liquid crystal composition, a liquid crystal color filter, an optical film, and a recording med...
|
|
JP2008531675A |
A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a compound of general formula: (I) wherein R1 and R2 together form a group —(CH...
|
|
JP4132153B2 |
|
|
JP2008164600A |
To provide a chemiluminescent electron-rich aryl-substituted 1,2-dioxetane compound.In the compound, an aryl group is multiply substituted with suitable electron-donating groups such that a light-emitting pattern of a molecule results in...
|
|
JP2008525409A |
The present invention pertains to certain 6-carboaryloxy-pyrazin-2-yl-carboaryl-amines of the following formula, and pharmaceutically acceptable salts thereof, which, inter alia, inhibit RAF (e.g., B-RAF) activity, inhibit cell prolifera...
|
|
JP2008156285A |
To provide a treating and/or preventing agent of chronic dermatological disorders (such as contact dermatitis, atopic dermatitis, seborrheic dermatitis, nummular eczema, lichen simplex chronicus Vidal, autosensitive dermatitis, stasis de...
|
|
JP2008156284A |
To provide an agent for treating and/or preventing itch accompanied by chronic cutis affection (e.g. atopic dermatitis, psoriasis, xeroderma, contact dermatitis, autosensitization dermatitis and asteatotic eczema).The agent for treating ...
|
|
JP2008520670A |
The present invention is directed to macrocyclic tertiary amine compounds represented by general formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase e...
|
|
JP4097697B2 |
PCT No. PCT/EP96/04506 Sec. 371 Date Apr. 20, 1998 Sec. 102(e) Date Apr. 20, 1998 PCT Filed Oct. 17, 1996 PCT Pub. No. WO97/14696 PCT Pub. Date Apr. 24, 1997Compounds of the general formula Ia and Ib are described in which R1 and R2 are ...
|
|
JP2008512374A |
The present invention relates to Diphenylethylene Compounds and compositions comprising a Diphenylethylene Compound. The present invention also relates to methods for preventing or treating various diseases and disorders by administering...
|
|
JP4074335B2 |
Chemiluminescent electron-rich aryl-substituted 1,2-dioxetane compounds are disclosed in which the aryl group is poly-substituted with suitable electron-donating groups such that the light-emitting pattern of the molecule results in a ve...
|
|
JP2008074801A |
To provide a hepatoprotector having antioxidation activity while protecting the liver to rapidly detox active and metabolize active oxygen species and to prevent its production and accumulation, especially a hepatoprotector which has a l...
|
|
JP4069987B2 |
A chemiluminescent assay method and compositions are described which use a haloalkoxy group-substituted dioxetane which is deprotected by a hydrolytic enzyme to undergo a chemiluminescent reaction. Chemiluminescent 1,2-dioxetane compound...
|
|
JP4065573B2 |
Cyclic products are prepared by selective olefin metathesis of bifunctional or polyfunctional substrates in the presence of one or several homogeneous or heterogeneous metathesis catalysts in a reaction medium. The invention is character...
|
|
JP4068144B2 |
A new class of stable dioxetanes bears a polycyclic stabilizing group and aryloxy moiety, the oxygen atom of which is provided with a protective group which can be removed by an enzymatic or chemical trigger admixed with the dioxetane. T...
|
|
JPWO2005092328A1 |
An object of the present invention is to provide a more potent therapeutic agent for hyperlipidemia. This is achieved by using a compound represented by the following formula (1) or (2) having FXR activity. [Chemical 1] [Chemical 2] [Sel...
|
|
JP2008503488A |
The present invention is directed to novel sulfamide and sulfamate derivatives, pharmaceutical compositions containing them and their use in the treatment of epilepsy and related disorders.
|
